Myriad Genetics Inc (MYGN)
Return on equity (ROE)
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -116,000 | -155,200 | -234,600 | -263,300 | -274,400 | -248,200 | -146,200 | -112,000 | -77,300 | -17,600 | -8,200 | -27,200 | -34,800 | -114,800 | -225,300 | -194,100 | -199,500 | -148,300 | -26,200 | -15,300 |
| Total stockholders’ equity | US$ in thousands | 731,700 | 740,500 | 760,000 | 783,200 | 683,400 | 735,200 | 835,200 | 885,800 | 916,600 | 947,400 | 950,100 | 967,800 | 968,600 | 902,500 | 875,200 | 909,300 | 918,200 | 967,200 | 1,077,200 | 1,074,500 |
| ROE | -15.85% | -20.96% | -30.87% | -33.62% | -40.15% | -33.76% | -17.50% | -12.64% | -8.43% | -1.86% | -0.86% | -2.81% | -3.59% | -12.72% | -25.74% | -21.35% | -21.73% | -15.33% | -2.43% | -1.42% |
September 30, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-116,000K ÷ $731,700K
= -15.85%
Myriad Genetics Inc's return on equity (ROE) has shown variability in recent quarters. The ROE has been negative, indicating that the company has not been generating satisfactory returns for its shareholders. The trend of decreasing ROE from September 2019 to March 2024 reflects a declining profitability and efficiency in the utilization of shareholders' equity.
The deteriorating ROE performance suggests potential issues within the company's operations, such as declining profitability, inefficient use of assets, or increasing debt levels. It is crucial for Myriad Genetics Inc to address these underlying factors to improve its ROE and enhance shareholder value in the future.
Peer comparison
Sep 30, 2024